中国癌症杂志 ›› 2017, Vol. 27 ›› Issue (3): 191-196.doi: 10.19401/j.cnki.1007-3639.2017.03.005

• 论著 • 上一篇    下一篇

血清CEA、CA125及CA72-4在胃癌腹膜转移中的临床意义

孙立秋,崔 海,崔 演,金文彪,崔玉珍,高爱花,沈雄虎   

  1. 延边大学附属医院肿瘤科,吉林 延吉133000
  • 出版日期:2017-03-30 发布日期:2017-04-12
  • 通信作者: 沈雄虎 E-mail:xim918@126.com
  • 基金资助:
    国家自然科学基金(81460366-H1617);吉林省教育厅“十二五”规划项目(2015)。

Clinical significance of serum CEA, CA125 and CA72-4 in gastric carcinoma with peritoneal metastasis

SUN Liqiu, CUI Hai, CUI Yan, JIN Wenbiao, CUI Yuzhen, GAO Aihua, SHEN Xionghu   

  1. Department of Oncology, Affiliated Hospital of Yanbian University, Yanji 133000, Jilin Province, China
  • Published:2017-03-30 Online:2017-04-12
  • Contact: SHEN Xionghu E-mail: xim918@126.com

摘要: 背景与目的:胃癌腹膜转移多处于疾病终末期,但每种肿瘤标志物在胃癌腹膜转移中的临床意义仍不是很明确。该研究探讨血清肿瘤标志物CEA、CA125及CA72-4在胃癌腹膜转移中的诊断价值及其临床意义。方法:收集延边大学附属医院肿瘤科2008年1月—2013年12月间经影像学、手术和病理学等检查确诊、并接受静脉及腹腔灌注化疗的108例胃癌腹膜转移患者为研究对象,分别于确诊时、每次化疗前检测血清CEA、CA125及CA72-4,分析单独、2或3种肿瘤标志物同时检测在胃癌腹膜转移的诊断敏感性,并分析其与临床病理因素、化疗疗效及生存期之间的相关性。结果:在胃癌腹膜转移患者CEA、CA125和CA72-4的阳性率各为20.4%、46.3%和45.4%,联合CEA/CA125、CEA/CA72-4、CA125/CA72-4及CEA/CA125/CA72-4的阳性率分别为54.7%、52.8%、69.5%和79.6%,3种标志物联合检测明显优于单独检测(P<0.05)。CEA、CA125和CA72-4水平均与ECOG分级存在相关性(P<0.05)。CA125阳性与腹水有关(P<0.001)。CA72-4阳性与卵巢转移相关(P<0.05)。确诊时血清CEA、CA125和CA72-4阳性患者中位生存期短于CEA、CA125和CA72-4阴性的患者(P<0.05)。在3周期化疗后3种肿瘤标志物较治疗前均下降,差异有统计学意义(P<0.05)。化疗后CA125下降与腹水量的减少有明显相关性(P<0.05)。确诊时肿瘤标志物阳性患者经化疗3个周期后转为阴性的患者生存期明显延长(P<0.001)。结论:联合检测血清CEA、CA125和CA72-4可明显提高胃癌腹膜转移的诊断率。

关键词: 肿瘤标志物, CEA, CA125, CA72-4, 胃癌, 腹膜转移

Abstract: Background and purpose: Peritoneal metastasis of gastric cancer is mainly discovered in the advanced cancer. Nonetheless, the clinical applicability of each tumor biomarker in peritoneal metastasis of gastric cancer is still ambiguous. Therefore, this study investigated the diagnostic value and clinical significance of CEA, CA125 and CA72-4 in gastric carcinoma patients with peritoneal metastases. Methods: A total of 108 gastric carcinoma patients with peritoneal metastases from Jan. 2008 to Dec. 2013 were studied. All patients were diagnosed by imaging, operations and pathological examination, and also received intravenous or intraperitoneal chemotherapy. Serum tumor markers such as CEA, CA125 and CA72-4 were determined during diagnosis and before each chemotherapy. The diagnostic sensitivity of single marker and combined detection with 2 or 3 markers were analyzed. The correlations among the serum tumor markers and clinical pathological factors, chemotherapeutic effects and survival time were analyzed. Results: Positive rates of CEA, CA125 and CA72-4 were 20.4%, 46.3% and 45.4% in gastric cancer patients with peritoneal metastases, respectively. For these patients, the positive rates of CEA/CA125, CEA/CA72-4, CA125/CA72-4 and CEA/CA125/CA72-4 were 54.7%, 52.8%, 69.5% and 79.6%, respectively. The combined detection of 3 tumor markers was much better than single marker detection (P<0.05). Positive rates of CEA, CA125 and CA72-4 were correlated with the ECOG scale (P<0.05). Positive rate of CA125 was associated with ascites (P<0.001), while positive rate of CA72-4 was associated with ovarian metastasis (P<0.05). Median survival time of patients with positive rates of CEA, CA125 and CA72-4 was significantly lower than that of the patients with normal levels of these markers (P<0.05). Compared with pre-treatment, the levels of all three tumor markers significantly declined after three cycles of chemotherapy (P<0.05). The decline in CA125 level after chemotherapy was significantly correlated with decreased amount of ascites (P<0.05). The tumor markers turned negative after 3 cycles chemotherapy in patients with positive markers upon initial diagnosis, their survival was significantly prolonged (P<0.001). Conclusion: Combined detection of serum CEA, CA125 and CA72-4 can significantly promote diagnostic rate of gastric cancer with peritoneal metastasis, and may be helpful in evaluating chemotherapeutic effects and predicting prognosis.

Key words: Tumor markers, CEA, CA125, CA72-4, Gastric cancer, Peritoneal metastasis